CN106458929A - N‑(氰基甲基)‑4‑(2‑(4‑吗啉代苯基氨基)嘧啶‑4‑基)苯甲酰胺盐酸盐 - Google Patents

N‑(氰基甲基)‑4‑(2‑(4‑吗啉代苯基氨基)嘧啶‑4‑基)苯甲酰胺盐酸盐 Download PDF

Info

Publication number
CN106458929A
CN106458929A CN201580031169.6A CN201580031169A CN106458929A CN 106458929 A CN106458929 A CN 106458929A CN 201580031169 A CN201580031169 A CN 201580031169A CN 106458929 A CN106458929 A CN 106458929A
Authority
CN
China
Prior art keywords
cyt
cyanomethyl
pyrimidin
morpholinophenylamino
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580031169.6A
Other languages
English (en)
Chinese (zh)
Inventor
B.H.布朗
E.A.卡拉
J.N.海明威
H.莫里森
T.雷诺兹
B.史
D.斯蒂芬尼迪斯
F.王
M.R.瓦尔
J.A.惠特尼
Y.辛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53674249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106458929(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to CN201910920874.1A priority Critical patent/CN110627728A/zh
Publication of CN106458929A publication Critical patent/CN106458929A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580031169.6A 2014-06-12 2015-06-11 N‑(氰基甲基)‑4‑(2‑(4‑吗啉代苯基氨基)嘧啶‑4‑基)苯甲酰胺盐酸盐 Pending CN106458929A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910920874.1A CN110627728A (zh) 2014-06-12 2015-06-11 N-(氰基甲基)-4-(2-(4-吗啉代苯基氨基)嘧啶-4-基)苯甲酰胺盐酸盐

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011315P 2014-06-12 2014-06-12
US62/011,315 2014-06-12
PCT/US2015/035316 WO2015191846A1 (en) 2014-06-12 2015-06-11 N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910920874.1A Division CN110627728A (zh) 2014-06-12 2015-06-11 N-(氰基甲基)-4-(2-(4-吗啉代苯基氨基)嘧啶-4-基)苯甲酰胺盐酸盐

Publications (1)

Publication Number Publication Date
CN106458929A true CN106458929A (zh) 2017-02-22

Family

ID=53674249

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580031169.6A Pending CN106458929A (zh) 2014-06-12 2015-06-11 N‑(氰基甲基)‑4‑(2‑(4‑吗啉代苯基氨基)嘧啶‑4‑基)苯甲酰胺盐酸盐
CN201910920874.1A Pending CN110627728A (zh) 2014-06-12 2015-06-11 N-(氰基甲基)-4-(2-(4-吗啉代苯基氨基)嘧啶-4-基)苯甲酰胺盐酸盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910920874.1A Pending CN110627728A (zh) 2014-06-12 2015-06-11 N-(氰基甲基)-4-(2-(4-吗啉代苯基氨基)嘧啶-4-基)苯甲酰胺盐酸盐

Country Status (36)

Country Link
US (5) US9469613B2 (https=)
EP (3) EP3907219A1 (https=)
JP (5) JP6600649B2 (https=)
KR (1) KR101928225B1 (https=)
CN (2) CN106458929A (https=)
AP (1) AP2016009551A0 (https=)
AR (1) AR100818A1 (https=)
AU (1) AU2015274554B9 (https=)
BR (1) BR112016028749A2 (https=)
CA (1) CA2951883C (https=)
CR (1) CR20160575A (https=)
CU (1) CU20160183A7 (https=)
CY (2) CY1123604T1 (https=)
DK (1) DK3154950T3 (https=)
EA (1) EA032639B1 (https=)
EC (1) ECSP16093323A (https=)
ES (1) ES2822773T3 (https=)
FI (1) FIC20240025I1 (https=)
FR (1) FR24C1030I2 (https=)
HR (1) HRP20201492T1 (https=)
HU (2) HUE051360T2 (https=)
IL (3) IL249038B (https=)
LT (2) LT3154950T (https=)
MA (1) MA40067A (https=)
MX (3) MX374541B (https=)
NL (1) NL301282I2 (https=)
NZ (1) NZ725966A (https=)
PH (1) PH12016502461A1 (https=)
PL (1) PL3154950T3 (https=)
PT (1) PT3154950T (https=)
RS (1) RS61065B1 (https=)
SG (2) SG10201911925TA (https=)
SI (1) SI3154950T1 (https=)
TW (3) TWI729644B (https=)
UY (1) UY36166A (https=)
WO (1) WO2015191846A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN115957221A (zh) * 2021-10-09 2023-04-14 广东东阳光药业有限公司 抗纤维化组合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US10245268B2 (en) 2016-08-10 2019-04-02 Sierra Oncology, Inc. Treatment of ACVR1-mediated diseases
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
WO2020041466A1 (en) 2018-08-21 2020-02-27 Sierra Oncology, Inc. Platelet count-agnostic methods of treating myelofibrosis
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US20250114371A1 (en) 2021-07-30 2025-04-10 Glaxosmithkline Llc Biomarker and patient selection in treatment for myelofibrosis
CA3228524A1 (en) 2021-08-10 2023-02-16 Bryan William STROUSE Momelotinib combination therapy
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
WO2023152773A1 (en) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Solid forms of momelotinib salts and improved processes for the preparation of momelotinib
CN119704552B (zh) * 2025-02-08 2025-06-13 泰州南洋塑料制品有限公司 一种电池槽注塑模具及边缘毛刺废料处理回收装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101861313A (zh) * 2007-03-12 2010-10-13 西托匹亚研究有限公司 苯基氨基嘧啶化合物及其用途
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5559714A (en) 1990-10-22 1996-09-24 Hallmark Cards, Incorporated Method and apparatus for display sequencing personalized social occasion products
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
CA2441733A1 (en) 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
CA2459794C (en) 2001-09-12 2012-08-21 Virexx Medical Corp. Vascular occlusion solid-phase agent with immobilised platelet binding agent
CA2486183C (en) 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AU2003286876A1 (en) 2002-11-01 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
US7259161B2 (en) 2002-11-04 2007-08-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
EP1560824A1 (en) 2002-11-05 2005-08-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
JP2008515986A (ja) 2004-10-13 2008-05-15 ワイス Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2016200866B2 (en) 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
AU2013201306B2 (en) 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
JP5611826B2 (ja) 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
US20100310563A1 (en) 2007-11-30 2010-12-09 Bumm Thomas G P Methods for treating induced cellular proliferative disorders
AU2009279825A1 (en) 2008-08-05 2010-02-11 Targegen, Inc. Methods of treating thalassemia
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
WO2010141946A1 (en) 2009-06-05 2010-12-09 Cell Targeting, Inc. Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
JP5086385B2 (ja) * 2010-03-08 2012-11-28 日立オートモティブシステムズ株式会社 電動パワーステアリング制御装置
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
WO2012149602A1 (en) 2011-05-02 2012-11-08 Ym Biosciences Australia Pty Ltd Multiple myeloma treatment
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
WO2014051056A1 (ja) * 2012-09-28 2014-04-03 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
ES2672468T3 (es) 2013-01-09 2018-06-14 Concert Pharmaceuticals Inc. Momelotinib deuterado
CN103965114B (zh) 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101861313A (zh) * 2007-03-12 2010-10-13 西托匹亚研究有限公司 苯基氨基嘧啶化合物及其用途
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN115957221A (zh) * 2021-10-09 2023-04-14 广东东阳光药业有限公司 抗纤维化组合物
CN115957221B (zh) * 2021-10-09 2026-01-06 广东东阳光药业股份有限公司 抗纤维化组合物

Also Published As

Publication number Publication date
USRE50497E1 (en) 2025-07-22
CY2024024I1 (el) 2025-03-28
KR101928225B1 (ko) 2018-12-11
TW201617323A (zh) 2016-05-16
CY1123604T1 (el) 2022-03-24
UY36166A (es) 2016-01-29
JP2021107465A (ja) 2021-07-29
CA2951883C (en) 2020-05-05
ECSP16093323A (es) 2017-01-31
BR112016028749A2 (pt) 2017-08-22
TWI729644B (zh) 2021-06-01
CU20160183A7 (es) 2017-05-10
IL276948B (en) 2021-09-30
US20160347719A1 (en) 2016-12-01
LTPA2024523I1 (https=) 2024-07-25
IL249038A0 (en) 2017-01-31
EP3907219A1 (en) 2021-11-10
US9469613B2 (en) 2016-10-18
EP3719005A1 (en) 2020-10-07
TW202012378A (zh) 2020-04-01
USRE48285E1 (en) 2020-10-27
MX374541B (es) 2025-03-06
CA2951883A1 (en) 2015-12-17
JP2023021454A (ja) 2023-02-10
CY2024024I2 (el) 2025-03-28
SG11201610079VA (en) 2016-12-29
JP2020059759A (ja) 2020-04-16
MX2019009564A (es) 2019-10-02
KR20170015496A (ko) 2017-02-08
HRP20201492T1 (hr) 2021-01-08
NZ725966A (en) 2018-04-27
MX2016016294A (es) 2017-09-01
CN110627728A (zh) 2019-12-31
TW202134236A (zh) 2021-09-16
DK3154950T3 (da) 2020-09-14
JP2017517535A (ja) 2017-06-29
JP6600649B2 (ja) 2019-10-30
IL276948A (en) 2020-10-29
US9809559B2 (en) 2017-11-07
EA032639B1 (ru) 2019-06-28
AU2015274554B9 (en) 2018-04-19
PH12016502461A1 (en) 2017-03-06
EP3154950B1 (en) 2020-08-05
FR24C1030I2 (fr) 2025-06-13
WO2015191846A1 (en) 2015-12-17
HUS2400025I1 (hu) 2024-08-28
JP2018184486A (ja) 2018-11-22
PL3154950T3 (pl) 2021-01-25
IL286442A (en) 2021-10-31
EP3154950A1 (en) 2017-04-19
AR100818A1 (es) 2016-11-02
LT3154950T (lt) 2020-11-25
MA40067A (fr) 2015-12-17
SI3154950T1 (sl) 2021-01-29
FR24C1030I1 (fr) 2024-08-30
USRE49445E1 (en) 2023-03-07
NL301282I2 (nl) 2025-03-12
TWI681954B (zh) 2020-01-11
IL249038B (en) 2020-09-30
EA201692356A1 (ru) 2017-07-31
JP7198867B2 (ja) 2023-01-04
ES2822773T3 (es) 2021-05-04
JP6840909B2 (ja) 2021-03-10
JP6883560B2 (ja) 2021-06-09
FIC20240025I1 (fi) 2024-07-12
HUE051360T2 (hu) 2021-03-01
MX2022015558A (es) 2023-01-30
RS61065B1 (sr) 2020-12-31
SG10201911925TA (en) 2020-01-30
AU2015274554A1 (en) 2016-11-24
CR20160575A (es) 2017-01-20
US20150361050A1 (en) 2015-12-17
PT3154950T (pt) 2020-10-09
AU2015274554B2 (en) 2018-02-15
AP2016009551A0 (en) 2016-11-30
JP7550205B2 (ja) 2024-09-12

Similar Documents

Publication Publication Date Title
JP7550205B2 (ja) Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩
US10479770B2 (en) Phosphatidylinositol 3-kinase inhibitors
TW201609105A (zh) 治療骨髓增生失調之療法
US10227350B2 (en) Phosphatidylinositol 3-kinase inhibitors
TW201627303A (zh) 磷脂醯肌醇３－激酶抑制劑
HK40063342A (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1236527A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1236527B (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1231079A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231079

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20170222

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1231079

Country of ref document: HK